A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease☆
Top Cited Papers
- 1 April 2004
- journal article
- clinical trial
- Published by Elsevier BV in Gastroenterology
- Vol. 126 (4), 989-996
- https://doi.org/10.1053/j.gastro.2004.01.012
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trialArthritis & Rheumatism, 2002
- IL-6 Is Required for the Development of Th1 Cell-Mediated Murine ColitisPublished by The American Association of Immunologists ,2000
- Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivoNature Medicine, 2000
- Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel diseaseJournal of Gastroenterology and Hepatology, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6.Gut, 1995
- Development of a Crohn's Disease Activity IndexGastroenterology, 1976